Rheumatoid arthritis: The two faces of Rsk2 in hyperplastic disease

Christopher Buckley, Jane Falconer

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
15 Downloads (Pure)


Given the established role of 90 kDa ribosomal S6 kinases (Rsk) in oncogenesis, and the promise of new Rsk-blocking cancer treatments, it is perhaps surprising that Rsk2-mediated inhibition of hyperplasia has now been demonstrated to occur in the arthritic synovium. Does this functional duality make Rsk2 a risky target for the treatment of rheumatoid arthritis?
Original languageEnglish
Pages (from-to)203-205
Number of pages3
JournalNature Reviews Rheumatology
Issue number4
Early online date27 Jan 2015
Publication statusPublished - Apr 2015


Dive into the research topics of 'Rheumatoid arthritis: The two faces of Rsk2 in hyperplastic disease'. Together they form a unique fingerprint.

Cite this